Issue 19 march 2021 Special Report Microbiota, treatment response and drug metabolism

Numéro 19 - Microbiota, treatment response and drug metabolism
Download for free

This new opus of La Revue des Microbiotes plunges us into the heart of what is still predominantly uncharted territory for microbiota specialists: pharmacology. The lexical field of the microbiota was recently enriched with a new term, pharmacomicrobiomics. This term refers to the study of how intra- or inter-individual variations of the microbiota affect the action, efficacy and toxicity of drugs.

In the fascinating report written by Patricia Lepage and Zehra Esra Ilhan, researchers at the INRAE's Micalis Institute specialising in the interactions between the gut microbiota and xenobiotics, we discover the true extent of bacteria's involvement in pharmacology. Thanks to their formidable enzymatic arsenal, the bacteria of the gut, but also of other anatomical sites (particularly the vagina, skin and lungs), are capable of influencing the bioavailability, efficacy and toxicity of drugs.

We learn, therefore, that the efficacy of drugs as routinely prescribed as digoxin (heart failure), nitrazepam (benzodiazepine), warfarin (oral anticoagulant) and levodopa (Parkinson's disease) is partly controlled by the gut microbiota. This is opening up a whole new realm of possibilities for pharmacologists.

To tell us more, Limoges University Pharmacologist Dr Roland Fabrice Lawson answers our questions on the prospects offered by this new branch of pharmacology, which include the ability to choose the right drug with personalised dose adaptation guided by individual microbiota mapping, intervention on the microbiota to increase a drug's activity, and the ability to predict those who will be non-responders before administering a costly therapy.

The innovation prospects are immense.

It is our great pleasure to share them with you in this 19th issue of La Revue des Microbiotes!

I hope you enjoy reading it.

Geneviève Héry-Arnaud
Editor in Chief of this issue

Read more

Table of contents

Special Report

  • Microbiota, treatment response and drug metabolismZehra Esra Ilhan, Patricia Lepage


  • Roland Fabrice Lawson

Microbiota News

  • The microbiota, a role in lung cancer Geneviève Héry-Arnaud
  • Ageing: the vascular protective effects of omega-3 relate to gut microbiota modifications Stanislas Bruley des Varannes
  • The blood lipid-reducing efficacy of statins depends on the gut microbiotaPhilippe Gérard
  • Human genetic determinants of the gut microbiota and their influence on human health Bruno Pot
  • Faecal microbiota transplantation: a new treatment for inflammatory colitis under immunotherapy?Cyrille Hoarau

In Brief

The Microbiota Chronicle

Taxonomic Reference


Dossier thématiquePatricia Lepage

Micalis Institut, INRAE, AgroParisTech, Paris-Saclay University, Paris, France

Dossier thématiqueZehra Esra Ilhan

Micalis Institut, INRAE, AgroParisTech, Paris-Saclay University, Paris, France

EntretienRoland Fabrice Lawson

Pharmacologist, Pharmacology Department, Pharmacy Faculty, Inserm U1248, Limoges, France


LoginFor free access to all issues & a notification upon publication of each new issue

Forgotten password ?

Password requestHave you forgotten your password? Enter your email address and we will send you a message with the password reset procedure.


Not yet registered ?

Create an account free of charge

Create an accountFor free access to all issues & a notification upon publication of each new issue

If you wish to subscribe to the paper version of La Revue des Microbiotes and have it delivered to your door, please contact our Subscription Department:

  • ?
  • As a result, I accept that my email address will be forwarded to the company PILEJE (SAS – French simplified joint stock company – with a capital of €1,190,400,00 - registered at the companies register in Paris under the number 950 450 452 – 37, Quai de Grenelle, 75738 PARIS Cedex 15)

The information included in this form is intended for the company LARENA, responsible for processing, for the purposes of processing your request and managing our relationship.

In accordance with French law no. 78-17 of 6 January 1978, as amended, and European Regulation 2016/679 of 27 April 2016, you have the right to access, correct, restrict or delete data concerning you or exercise your right to opposition or right to portability. You can exercise these rights by making a request in writing, accompanied by proof of identity, to LARENA – DPO – 1 ZI du Taillis – Champtoceaux – 49270 Orée d’Anjou, France or to

For more information about the management of your personal data

*These fields are required to process your request. Without this information, we will be unable to process your request .

Already registered


Sample copyAccess the first issue free of charge without creating an account

Numéro 1 - Microorganisms and mankind
5 years of La Revue des Microbiotes !Watch the video